How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
55
ACRS Quote, Financials, Valuation and Earnings
Last price:
$3.47
Seasonality move
:
26.08%
Day range:
$3.51 - $3.92
52-week range:
$1.05 - $4.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
25.80x
P/B ratio:
3.17x
Volume:
1.6M
Avg. volume:
2.5M
1-year change:
46.86%
Market cap:
$380.3M
Revenue:
$18.7M
EPS (TTM):
-$1.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ACRS
Aclaris Therapeutics, Inc.
|
$1.9M | -$0.14 | 58.08% | -21.75% | $7.67 |
|
CORT
Corcept Therapeutics, Inc.
|
$255.3M | $0.30 | 27.74% | -71.78% | $94.20 |
|
NEPH
Nephros, Inc.
|
$4.5M | $0.01 | 15.01% | -69.79% | $6.50 |
|
PBYI
Puma Biotechnology, Inc.
|
$68.6M | $0.23 | 16.12% | -41.13% | $5.00 |
|
PRLD
Prelude Therapeutics, Inc.
|
$20.5M | -$0.18 | 412.5% | -65.45% | $4.00 |
|
VVOS
Vivos Therapeutics, Inc.
|
$7.1M | -$0.48 | 91.91% | -0.69% | $5.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ACRS
Aclaris Therapeutics, Inc.
|
$3.51 | $7.67 | $380.3M | -- | $0.00 | 0% | 25.80x |
|
CORT
Corcept Therapeutics, Inc.
|
$45.85 | $94.20 | $4.8B | 52.39x | $0.00 | 0% | 7.40x |
|
NEPH
Nephros, Inc.
|
$4.51 | $6.50 | $47.9M | 32.66x | $0.00 | 0% | 2.71x |
|
PBYI
Puma Biotechnology, Inc.
|
$6.32 | $5.00 | $318.5M | 8.53x | $0.00 | 0% | 1.49x |
|
PRLD
Prelude Therapeutics, Inc.
|
$1.97 | $4.00 | $123.8M | -- | $0.00 | 0% | 13.29x |
|
VVOS
Vivos Therapeutics, Inc.
|
$1.71 | $5.00 | $15.4M | -- | $0.00 | 0% | 0.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ACRS
Aclaris Therapeutics, Inc.
|
1.83% | 2.539 | 1.09% | 3.92x |
|
CORT
Corcept Therapeutics, Inc.
|
1% | -3.281 | 0.07% | 2.85x |
|
NEPH
Nephros, Inc.
|
10.34% | 3.066 | 2.3% | 3.17x |
|
PBYI
Puma Biotechnology, Inc.
|
26.26% | 0.733 | 15.34% | 1.57x |
|
PRLD
Prelude Therapeutics, Inc.
|
23.37% | -0.793 | 21.91% | 3.02x |
|
VVOS
Vivos Therapeutics, Inc.
|
83.15% | 1.547 | 48.77% | 0.77x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ACRS
Aclaris Therapeutics, Inc.
|
$850K | -$17M | -102.07% | -103.93% | -516.79% | -$11M |
|
CORT
Corcept Therapeutics, Inc.
|
$203M | $10.2M | 15.84% | 16% | 4.92% | $54.5M |
|
NEPH
Nephros, Inc.
|
$2.9M | $314K | 14.16% | 16.22% | 6.59% | $99K |
|
PBYI
Puma Biotechnology, Inc.
|
$42.3M | $9.6M | 23.32% | 38.49% | 17.57% | $9.7M |
|
PRLD
Prelude Therapeutics, Inc.
|
$6.1M | -$20.4M | -90.83% | -106.36% | -314.12% | -$19.1M |
|
VVOS
Vivos Therapeutics, Inc.
|
$3.6M | -$4.7M | -153.33% | -315.1% | -69.79% | -$4.1M |
Aclaris Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ACRS or CORT?
Corcept Therapeutics, Inc. has a net margin of -442.98% compared to Aclaris Therapeutics, Inc.'s net margin of 9.32%. Aclaris Therapeutics, Inc.'s return on equity of -103.93% beat Corcept Therapeutics, Inc.'s return on equity of 16%.
Company Gross Margin Earnings Per Share Invested Capital ACRSAclaris Therapeutics, Inc.25.77% -$0.12 $122.3M CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M -
What do Analysts Say About ACRS or CORT?
Aclaris Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 118.42%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $94.20 which suggests that it could grow by 105.45%. Given that Aclaris Therapeutics, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe Aclaris Therapeutics, Inc. is more attractive than Corcept Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACRSAclaris Therapeutics, Inc.5 1 0 CORTCorcept Therapeutics, Inc.3 1 1 -
Is ACRS or CORT More Risky?
Aclaris Therapeutics, Inc. has a beta of 0.416, which suggesting that the stock is 58.421% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.232, suggesting its less volatile than the S&P 500 by 76.804%.
-
Which is a Better Dividend Stock ACRS or CORT?
Aclaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aclaris Therapeutics, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACRS or CORT?
Aclaris Therapeutics, Inc. quarterly revenues are $3.3M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. Aclaris Therapeutics, Inc.'s net income of -$14.6M is lower than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, Aclaris Therapeutics, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 52.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aclaris Therapeutics, Inc. is 25.80x versus 7.40x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACRSAclaris Therapeutics, Inc.25.80x -- $3.3M -$14.6M CORTCorcept Therapeutics, Inc.7.40x 52.39x $207.6M $19.4M
-
Which has Higher Returns ACRS or NEPH?
Nephros, Inc. has a net margin of -442.98% compared to Aclaris Therapeutics, Inc.'s net margin of 7.07%. Aclaris Therapeutics, Inc.'s return on equity of -103.93% beat Nephros, Inc.'s return on equity of 16.22%.
Company Gross Margin Earnings Per Share Invested Capital ACRSAclaris Therapeutics, Inc.25.77% -$0.12 $122.3M NEPHNephros, Inc.60.47% $0.03 $11.2M -
What do Analysts Say About ACRS or NEPH?
Aclaris Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 118.42%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 44.12%. Given that Aclaris Therapeutics, Inc. has higher upside potential than Nephros, Inc., analysts believe Aclaris Therapeutics, Inc. is more attractive than Nephros, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACRSAclaris Therapeutics, Inc.5 1 0 NEPHNephros, Inc.1 0 0 -
Is ACRS or NEPH More Risky?
Aclaris Therapeutics, Inc. has a beta of 0.416, which suggesting that the stock is 58.421% less volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.407, suggesting its more volatile than the S&P 500 by 40.722%.
-
Which is a Better Dividend Stock ACRS or NEPH?
Aclaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aclaris Therapeutics, Inc. pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACRS or NEPH?
Aclaris Therapeutics, Inc. quarterly revenues are $3.3M, which are smaller than Nephros, Inc. quarterly revenues of $4.8M. Aclaris Therapeutics, Inc.'s net income of -$14.6M is lower than Nephros, Inc.'s net income of $337K. Notably, Aclaris Therapeutics, Inc.'s price-to-earnings ratio is -- while Nephros, Inc.'s PE ratio is 32.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aclaris Therapeutics, Inc. is 25.80x versus 2.71x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACRSAclaris Therapeutics, Inc.25.80x -- $3.3M -$14.6M NEPHNephros, Inc.2.71x 32.66x $4.8M $337K
-
Which has Higher Returns ACRS or PBYI?
Puma Biotechnology, Inc. has a net margin of -442.98% compared to Aclaris Therapeutics, Inc.'s net margin of 16.24%. Aclaris Therapeutics, Inc.'s return on equity of -103.93% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.
Company Gross Margin Earnings Per Share Invested Capital ACRSAclaris Therapeutics, Inc.25.77% -$0.12 $122.3M PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M -
What do Analysts Say About ACRS or PBYI?
Aclaris Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 118.42%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $5.00 which suggests that it could fall by -20.89%. Given that Aclaris Therapeutics, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Aclaris Therapeutics, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACRSAclaris Therapeutics, Inc.5 1 0 PBYIPuma Biotechnology, Inc.0 1 0 -
Is ACRS or PBYI More Risky?
Aclaris Therapeutics, Inc. has a beta of 0.416, which suggesting that the stock is 58.421% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.747%.
-
Which is a Better Dividend Stock ACRS or PBYI?
Aclaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aclaris Therapeutics, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACRS or PBYI?
Aclaris Therapeutics, Inc. quarterly revenues are $3.3M, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Aclaris Therapeutics, Inc.'s net income of -$14.6M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Aclaris Therapeutics, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 8.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aclaris Therapeutics, Inc. is 25.80x versus 1.49x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACRSAclaris Therapeutics, Inc.25.80x -- $3.3M -$14.6M PBYIPuma Biotechnology, Inc.1.49x 8.53x $54.5M $8.8M
-
Which has Higher Returns ACRS or PRLD?
Prelude Therapeutics, Inc. has a net margin of -442.98% compared to Aclaris Therapeutics, Inc.'s net margin of -303.46%. Aclaris Therapeutics, Inc.'s return on equity of -103.93% beat Prelude Therapeutics, Inc.'s return on equity of -106.36%.
Company Gross Margin Earnings Per Share Invested Capital ACRSAclaris Therapeutics, Inc.25.77% -$0.12 $122.3M PRLDPrelude Therapeutics, Inc.93.46% -$0.26 $76.4M -
What do Analysts Say About ACRS or PRLD?
Aclaris Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 118.42%. On the other hand Prelude Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 103.05%. Given that Aclaris Therapeutics, Inc. has higher upside potential than Prelude Therapeutics, Inc., analysts believe Aclaris Therapeutics, Inc. is more attractive than Prelude Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACRSAclaris Therapeutics, Inc.5 1 0 PRLDPrelude Therapeutics, Inc.2 0 0 -
Is ACRS or PRLD More Risky?
Aclaris Therapeutics, Inc. has a beta of 0.416, which suggesting that the stock is 58.421% less volatile than S&P 500. In comparison Prelude Therapeutics, Inc. has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.343%.
-
Which is a Better Dividend Stock ACRS or PRLD?
Aclaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prelude Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aclaris Therapeutics, Inc. pays -- of its earnings as a dividend. Prelude Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACRS or PRLD?
Aclaris Therapeutics, Inc. quarterly revenues are $3.3M, which are smaller than Prelude Therapeutics, Inc. quarterly revenues of $6.5M. Aclaris Therapeutics, Inc.'s net income of -$14.6M is higher than Prelude Therapeutics, Inc.'s net income of -$19.7M. Notably, Aclaris Therapeutics, Inc.'s price-to-earnings ratio is -- while Prelude Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aclaris Therapeutics, Inc. is 25.80x versus 13.29x for Prelude Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACRSAclaris Therapeutics, Inc.25.80x -- $3.3M -$14.6M PRLDPrelude Therapeutics, Inc.13.29x -- $6.5M -$19.7M
-
Which has Higher Returns ACRS or VVOS?
Vivos Therapeutics, Inc. has a net margin of -442.98% compared to Aclaris Therapeutics, Inc.'s net margin of -79.61%. Aclaris Therapeutics, Inc.'s return on equity of -103.93% beat Vivos Therapeutics, Inc.'s return on equity of -315.1%.
Company Gross Margin Earnings Per Share Invested Capital ACRSAclaris Therapeutics, Inc.25.77% -$0.12 $122.3M VVOSVivos Therapeutics, Inc.52.38% -$0.49 $15M -
What do Analysts Say About ACRS or VVOS?
Aclaris Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 118.42%. On the other hand Vivos Therapeutics, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 192.4%. Given that Vivos Therapeutics, Inc. has higher upside potential than Aclaris Therapeutics, Inc., analysts believe Vivos Therapeutics, Inc. is more attractive than Aclaris Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACRSAclaris Therapeutics, Inc.5 1 0 VVOSVivos Therapeutics, Inc.2 1 0 -
Is ACRS or VVOS More Risky?
Aclaris Therapeutics, Inc. has a beta of 0.416, which suggesting that the stock is 58.421% less volatile than S&P 500. In comparison Vivos Therapeutics, Inc. has a beta of 6.895, suggesting its more volatile than the S&P 500 by 589.464%.
-
Which is a Better Dividend Stock ACRS or VVOS?
Aclaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vivos Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aclaris Therapeutics, Inc. pays -- of its earnings as a dividend. Vivos Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACRS or VVOS?
Aclaris Therapeutics, Inc. quarterly revenues are $3.3M, which are smaller than Vivos Therapeutics, Inc. quarterly revenues of $6.8M. Aclaris Therapeutics, Inc.'s net income of -$14.6M is lower than Vivos Therapeutics, Inc.'s net income of -$5.4M. Notably, Aclaris Therapeutics, Inc.'s price-to-earnings ratio is -- while Vivos Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aclaris Therapeutics, Inc. is 25.80x versus 0.85x for Vivos Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACRSAclaris Therapeutics, Inc.25.80x -- $3.3M -$14.6M VVOSVivos Therapeutics, Inc.0.85x -- $6.8M -$5.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.61% over the past day.
Buy
71
CLS alert for Jan 29
Celestica, Inc. [CLS] is down 15% over the past day.
Buy
58
AAOI alert for Jan 29
Applied Optoelectronics, Inc. [AAOI] is down 12.82% over the past day.
